遗传性血管与正常C1抑制剂的全球频率,诊断和治疗
Markus Magerl1,2, Marc A Riedl3, Luisa Karla Arruda4
1Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
具有正常C1抑制剂 (HAE-nC1INH) 的遗传性血管可能比想象中的更常见. 目前的诊断和治疗在全球范围内各不相同,这凸显了对HAE-nC1INH的标准化方法和向治疗的需要.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 罕见疾病 罕见疾病
背景情况:
- 遗传性血管 (HAE) 是一种罕见的遗传性疾病.
- 具有正常C1抑制剂的HAE (HAE-nC1INH) 缺乏标准化的诊断测试.
- 这限制了HAE-nC1INH的流行率估计和治疗指南.
研究的目的:
- 描述HAE-nC1INH的全球频率.
- 概述HAE-nC1INH.的诊断途径.
- 详细说明HAE-nC1INH目前的治疗模式.
主要方法:
- 在15个国家的30个中心的30名董事会认证的HAE治疗医生的在线调查.
- 在2022年12月至2023年4月期间进行的调查.
- 医生报告了患者数量,诊断方法和使用的治疗方法.
主要成果:
- 在之前的12个月中,医生平均治疗了71名HAE患者.
- 估计HAE-nC1INH占HAE病例的24%,主要是在成年人中.
- 诊断通常涉及家族病史,C4水平和C1功能/水平;治疗范围很大.
- 未满足的需求包括针对HAE-nC1INH的特定治疗和口服治疗选择.
结论:
- 可能低估了HAE-nC1INH的患病率.
- 在全球范围内,HAE-nC1INH诊断和治疗存在显著的变异性.
- 开发验证的生物标志物和基于机制的治疗方法对于推动HAE-nC1INH管理至关重要.
更多相关视频
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angle Closure Glaucoma: Treatment
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
